Biotech Values

[drbio45]

the isis drug

from the article you sited

Elevations in liver transaminases (ALT) were observed in this high-dose cohort; five of the eight patients dosed at 400 mg/week, including all four patients with undetectable levels of apoB, experienced modest ALT elevations at or above three times the upper limit of normal (3xULN). No patients experienced ALT elevations greater than 5xULN; the maximal ALT observed was 241 IU/L. Importantly, no patients evidenced liver chemistries that would suggest risk of liver injury (extremely high ALT or ALT elevations together with elevations in bilirubin greater than 2xULN). The mild increases in ALT at the 400 mg/week dose likely reflect extreme lipid-lowering activity, not toxicity

I am surprised you didn't comment about this. I don't believe the drug could get approved or a partnerhip deal signed with the alt elevations observed. The company says they don't believe it is liver toxicity.

They have a really long way to convince most people of that.